

REMARKS

Reconsideration of the instant application in view of the foregoing is urgently requested.

Claim 22 has been amended only as to clarity as suggested by the Examiner. Accordingly since claim 22 is now in proper form it should be allowed and thus, claims 8-10, 29, 31, 33, 35, 36 and 39 that depend on claim 22 should likewise be allowed.

Applicant wishes to retain claim 11, since applicant has prior submitted a revised Sequence Listing which includes SEQ ID NO 41 and such Sequence Listing was fully accepted by the Sequence Listing operation lead by Mark Spencer. All other objections relating to the perceived lack of a proper Sequence Listing have thereby been obviated.

The Examiner has also *de novo* objected to the unmarked sequences in the specification. Applicant has deleted the objected to sequences and inserted a reference to a U.S. patent which is the U.S. counterpart to the EP 0 941 318 B1 which was part of the original disclosure. Applicant states that by eliminating the sequences and inserting a reference to the U.S. Patent no new matter has been introduced into the disclosure.

Based on the foregoing, allowance of claims 8-11, 22, 23, 25, 27, 29-36 and 39-42 is respectfully requested.

CONCLUSION

In view of the above, each of the presently pending claims in this application is believed to be in immediate conditions for allowance. Accordingly, the Examiner is respectfully requested to withdraw the outstanding rejections of the claims and to pass this application to issue.

Should the Examiner consider necessary or desirable any formal changes anywhere in the specification, claims and/or drawing, then it is respectfully

requested that such changes be made by Examiner's Amendment, if the Examiner feels this would facilitate passage of the case to issuance. If the Examiner feels that it might be helpful in advancing this case by calling the undersigned, applicant would greatly appreciate such a telephone interview.

Respectfully submitted,

By: 

Ursula B. Day
Attorney for Applicant
Reg. No. 47,296

Date: August 31, 2010
708 Third Avenue
Suite 1501
New York, N.Y. 10017
(212) 244-5500
UBD:pn